FBRX vs HSIC
Forte Biosciences, Inc. vs Henry Schein — AI-powered side-by-side comparison
FBRX
Forte Biosciences, Inc.
59
Watch
VS
| Metric | FBRX | HSIC |
|---|
| AI Score |
59
|
67
|
| Price |
$76.88
|
$89.16
|
| P/E Ratio |
-16.78×
|
25.77×
|
| ROE |
-113.7%
|
12.3%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
0.0%
|
30.3%
|
| Debt / Equity |
0.00×
|
1.21×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
85.6
|
59.4
|
| Beta |
2.645
|
0.808
|
| Expected Upside |
—
|
+0.8%
|
AI Committee View
Current Innellis committee reasoning for FBRX versus HSIC.
HSIC leads by 8 points.
HSIC scores 67/100 (Buy) versus FBRX at 59/100 (Watch).
FBRX Committee View
50% agreement
4 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 80.8% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- RSI at 86 is in overbought territory — Technical
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 92 -- overbought on the larger timeframe too — Technical
HSIC Committee View
75% agreement
4 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is growth rate is decelerating quarter over quarter -- the trend line matters more than the level. The committee is constructive but not yet at full conviction.
Bull Case
- 4 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth